Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$70.33
-0.7%
$65.76
$53.16
▼
$97.59
$2.10B1.03510,340 shs113,948 shs
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
$27.66
-2.2%
$27.57
$17.34
▼
$31.99
$1.64B0.45361,585 shs29,719 shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$74.21
-1.8%
$81.09
$74.12
▼
$118.01
$1.70B0.51276,526 shs28,421 shs
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
$3.38
+0.4%
$2.41
$1.53
▼
$5.60
$533.93M7.31322,030 shs4,479 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
+1.86%+0.16%+21.52%-1.01%+9.65%
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
+0.07%-10.56%-3.68%+3.78%+10.29%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
-0.68%-4.68%-8.18%-8.19%-12.60%
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
-0.59%-31.57%+59.24%+10.89%-37.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$70.33
-0.7%
$65.76
$53.16
▼
$97.59
$2.10B1.03510,340 shs113,948 shs
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
$27.66
-2.2%
$27.57
$17.34
▼
$31.99
$1.64B0.45361,585 shs29,719 shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$74.21
-1.8%
$81.09
$74.12
▼
$118.01
$1.70B0.51276,526 shs28,421 shs
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
$3.38
+0.4%
$2.41
$1.53
▼
$5.60
$533.93M7.31322,030 shs4,479 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
+1.86%+0.16%+21.52%-1.01%+9.65%
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
+0.07%-10.56%-3.68%+3.78%+10.29%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
-0.68%-4.68%-8.18%-8.19%-12.60%
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
-0.59%-31.57%+59.24%+10.89%-37.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
2.80
Moderate Buy$95.0035.08% Upside
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
2.50
Moderate Buy$29.004.85% Upside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.38
Hold$108.2545.87% Upside
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ZJYL, ESTA, LMAT, and KMTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/5/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Lower Price TargetEqual Weight$94.00 ➝ $86.00
11/5/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Reiterated RatingMarket Outperform
11/5/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Initiated CoverageMarket Outperform$127.00 ➝ $110.00
10/29/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Lower Price TargetBuy$103.00 ➝ $93.00
10/26/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Lower Price TargetBuy$117.00 ➝ $95.00
10/23/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
DowngradeBuy (B-) ➝ Hold (C+)
10/20/2026
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
Initiated CoverageOutperform$34.00
10/15/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Reiterated RatingBuy$117.00
10/14/2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Initiated CoverageBuy$85.00
10/8/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
UpgradeHold (C+) ➝ Buy (B-)
9/25/2026
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
Reiterated RatingSell (D)
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$264.03M7.94N/AN/A$0.52 per share135.25
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
$106.73M15.44N/AN/A$4.45 per share6.22
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$269.36M6.30$2.83 per share26.22$18.89 per share3.93
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
$20.69M25.81$0.18 per share18.42$3.78 per share0.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$51.06M-$1.28N/AN/AN/A-14.56%-196.38%-10.45%N/A
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
-$131.61M-$2.67N/AN/AN/A-140.43%-63.83%-44.76%N/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$57.73M$2.7526.9623.562.2423.51%15.33%9.97%N/A
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
$1.19MN/AN/AN/AN/AN/AN/AN/AN/A

Latest ZJYL, ESTA, LMAT, and KMTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.6860$0.65-$0.0360$0.65$67.39 million$67.97 million
10/30/2026Q3 2026
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$0.2568-$0.35-$0.0932-$0.35$66.81 million$71.99 million
9/14/2026Q1 2027
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
-$0.61-$0.75-$0.14-$0.75N/A$30.97 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
N/AN/AN/AN/AN/A
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$1.001.35%+16.05%36.36%14 Years
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
N/AN/AN/AN/AN/A

Latest ZJYL, ESTA, LMAT, and KMTS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
quarterly$0.251.35%11/19/202611/19/202612/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
17.17
3.57
2.38
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
0.33
4.69
4.69
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
0.39
14.60
12.54
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
0.10
1.95
1.70
CompanyEmployeesShares OutstandingFree FloatOptionable
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
1,00429.82 million26.84 millionOptionable
Kestra Medical Technologies, Ltd. stock logo
KMTS
Kestra Medical Technologies
44359.56 million56.41 millionN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
65522.88 million21.19 millionOptionable
Jin Medical International Ltd. stock logo
ZJYL
Jin Medical International
273158.20 millionN/ANot Optionable

Recent News About These Companies

JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
Jin Medical International Ltd. Class A
Jin Medical International

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Establishment Labs stock logo

Establishment Labs NASDAQ:ESTA

$70.33 -0.47 (-0.66%)
As of 11:11 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Kestra Medical Technologies stock logo

Kestra Medical Technologies NASDAQ:KMTS

$27.66 -0.63 (-2.23%)
As of 11:12 AM Eastern
This is a fair market value price provided by Massive. Learn more.

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S. The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm. The ASSURE WCD was purpose-built to enhance patient comfort and compliance and directly address the key barriers to adoption associated with the only other commercially available WCD. We believe the ASSURE WCD offers significant clinical and functional advantages, including greater patient compliance as a result of a major reduction in false alarms and enhanced comfort and wearability. In addition to the ASSURE WCD, our Cardiac Recovery System platform includes a comprehensive suite of fully integrated digital solutions and services that enable enhanced patient and provider engagement and oversight, with the objective of improving patient outcomes. We believe our Cardiac Recovery System platform addresses serious unmet needs in the cardiac patient population and has the potential to disrupt and grow the market which has been limited to a single solution for more than 20 years. As of January 31, 2025, our system is actively being prescribed by more than 550 hospitals across the U.S., representing approximately 20% of WCD prescribing hospitals in the U.S., and has been worn by over 17,000 patients since it was fully commercially launched. In our top 50 hospitals, we believe we have successfully captured approximately 45% of the currently available prescriptions based on company-sourced data on all hospitals that we serve in the U.S. and the percentage of WCD filled prescriptions at those hospitals that are for our ASSURE WCD. SCA is a life-threatening emergency characterized by the abrupt cessation of the heartbeat caused by an electrical malfunction in the heart. This is typically triggered by ventricular arrhythmias, such as ventricular fibrillation (“VF”), and leads to a loss of consciousness and potentially death within minutes if not promptly treated. The American Heart Association (“AHA”) estimates that SCA causes approximately 436,000 deaths per year, making it the third leading cause of death in the U.S. Defibrillation, or an electrical shock, is the only way to restore a fibrillating heart to a normal rhythm. Each minute of delay in restoring the heart to a normal rhythm reduces a patient’s chance of survival by 7% to 10%. The average time for Emergency Medical Services (“EMS”) arrival is 7 minutes from the time of a 911 call, and often longer in rural communities. The most common location of a SCA in adults is at a home or residence, representing approximately 73% of SCAs. In addition, approximately 50% of all SCAs are unwitnessed. A WCD is a wearable, non-invasiveminiaturized automated external defibrillator and is worn underneath regular clothing. The device continuously monitors a patient’s heart rhythm and is capable of delivering a defibrillation shock. Wires connect electrodes inside the garment to the monitor, which is carried in a small pack or shoulder bag. The electrodes continuously acquire a patient’s heart rate and rhythm for evaluation by the automated external defibrillator. If the monitor detects a potentially life-threatening arrhythmia, the WCD first alerts the patient via an audible alarm and then administers a shock, if needed. For over 20 years, WCDs have been used to protect patients at elevated risk of SCA. However, until the ASSURE WCD received Food and Drug Administration (“FDA”) approval in July of 2021, the market was limited to a single solution. Since the approval of the first WCD in 2001, global WCD revenues have grown to $1.3 billion in 2023, with approximately 85% of the revenues generated in the U.S based on our analysis of third-party claims data and estimated average WCD wear prescription lengths and average reimbursement rates in the U.S. and in select international markets derived from industry data and internal estimates. The volume of patients prescribed a WCD in the U.S. grew at roughly 6% annually between 2021 and 2023, and we expect WCD revenues to continue growing. Despite being proven as safe and effective in treating dangerous cardiac rhythms when worn, WCD therapy remains underutilized, reaching just 14% of the eligible U.S. patient population in 2023 based on data on patients indicated for a WCD and WCD prescription data from industry sources. We believe that the low penetration of WCD therapy is largely due to the limitations of the incumbent commercially available device. In feedback we have collected through directly engaging with patients and providers and customer feedback on public platforms, commonly cited reasons for patients or providers failing to use the competitor device include high false alarm frequency, poor wearability and patient discomfort, a unisex-only garment, low utility data and limited connectivity with patients. In the U.S., we estimate that there are approximately 800,000 cardiac patients each year who have experienced a myocardial infarction (“MI”) or are diagnosed with heart failure and have low Left Ventricular Ejection Fraction (“LVEF”), therefore making them eligible for WCD therapy. Additionally, approximately 50,000 patients each year either have documented ventricular tachycardia (“VT”) or VF, an inherited genetic condition, or have had their implantable cardioverter defibrillators (“ICD”) temporarily explanted, and are also indicated for WCDs. Based on an average WCD wear prescription length of 3.4 months per patient and an average Medicare reimbursement rate of $3,436 per patient per month, we believe this represents an approximately $10 billion annual addressable market. In select international markets, we estimate based on patient population data collected by various third-party industry sources that there are approximately 3.7 million people each year who experience an MI, are diagnosed with heart failure, have documented VT or VF, have an inherited genetic condition, or have had their ICD temporarily explanted. Among these patients, based on the same third-party industry sources, we estimate that approximately 1.8 million patients meet the indications for WCD therapy. Based on estimated average WCD wear prescription length in these international markets of 2.5 months per patient and estimated average reimbursement rate of $3,000 per patient per month derived from industry data and internal estimates, we believe this represents an approximately $14 billion total annual market opportunity outside the U.S. The ASSURE WCD is the next generation of WCD therapy, delivering a safe and effective solution for patients with a design that enhances patient comfort and compliance. In addition to the ASSURE WCD, the various digital solutions and services of our Cardiac Recovery System platform include the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services. The ASSURE patient application engages patients with real-time mobile updates to promote compliance, while the Kestra CareStation remote patient data platform equips healthcare providers with actionable insights to support timely and informed care decisions. Heart Alert Services and ASSURE Assist services work together to enhance safety and are designed to provide critical alerts to healthcare providers for significant arrhythmias and notify emergency services when therapy is administered. This post-therapy EMS support is critical as a range of injuries, such as head injuries, soft tissue damage and bone fractures, can result from falling down after a SCA. In addition, the ASSURE wearable ECG as part of our Cardiac Recovery System platform provides monitoring and connectivity for patients no longer indicated for a WCD but who still require ongoing support while their heart continues to remodel. We believe we offer the most comprehensive and cohesive platform, with digital solutions and services that are seamlessly integrated with our ASSURE WCD, meaningfully differentiating our Cardiac Recovery System platform from the only other commercially available WCD. We are building a body of clinical evidence supporting the safety, efficacy, and benefits of the ASSURE WCD, with six publications completed to date. This growing portfolio includes our pivotal trials—the ASSURE WCD Clinical Evaluation—Detection and Safety Study (“ACE-DETECT”) and the ASSURE WCD Clinical Evaluation—Conversion Efficacy Study (“ACE-CONVERT”)—which served as the basis for our premarket approval (“PMA”). In addition, we are conducting the ASSURE WCD Clinical Evaluation—Post Approval Study (“ACE-PAS”) as part of a broader ongoing ASSURE Patient Registry. All patients prescribed the ASSURE WCD in the United States after August 5, 2022 are included in the Registry. As of January 31, 2025, our ongoing registry has enrolled over 17,000 patients, and its findings further validate the results of ACE-DETECT and ACE-CONVERT. Our most recent FDA submission from ACE-PAS from July 2024, which includes data from 5,929 patients, reported first shock conversion efficacy of approximately 96%, a low false alarm rate with only 6% of our patients experiencing a false alarm, compared to 46% for the competitor’s device, and a median daily use of 23.2 hours. These results underscore the ASSURE WCD’s competitive advantages in wearability, usability, and patient compliance, providing strong support for continued adoption. We believe this collection of real-world evidence will generate additional publications, continue to increase awareness of WCDs as a proven therapy for elevated risk cardiac patients and further demonstrate the clinical differentiation of our ASSURE WCD. We have made material investments in infrastructure to support rapid growth and scalability, specifically in our commercial organization, distribution and supply chain capabilities, as well as revenue cycle management capabilities. In the U.S., we have built a commercial sales team of approximately 70 direct sales representatives and more than 40 sales and clinical support professionals with deep expertise in cardiac rhythm management and established relationships in the cardiology and electrophysiology fields. This team is responsible for developing sales territory business plans, targeting and opening new accounts, and processing prescriptions of our ASSURE WCD. Our direct sales team is supported by a contracted team of over 250 ASSURE Patient Specialists (“APSs”) who assist patients with fitting and training. At fitting, we deliver our ASSURE WCD from our distribution network to the patient. We utilize a lease business model, and when a patient’s wear time has concluded, the device is returned for reprocessing and reintroduction into the distribution network. To support our growth, we have developed a highly scalable supply chain in collaboration with experienced, top-tier medical technology suppliers. Our substantial investment in a fleet of devices, each with a capacity for approximately three patient wears per year, are reprocessed through efficient reconditioning, which enables the business to scale with an attractive unit economic profile. Finally, our revenue cycle management capabilities streamline reimbursement processes by ensuring claims are accurately prepared and submitted according to individual payor requirements, facilitating timely collections. These capabilities are a critical asset in driving operational efficiency and supporting both patient and prescriber satisfaction. We believe our significant investments in infrastructure create a high barrier to entry that will help us protect and grow our market share. Kestra Medical Technologies, Ltd. is located in Kirkland, Washington.

LeMaitre Vascular stock logo

LeMaitre Vascular NASDAQ:LMAT

$74.21 -1.37 (-1.81%)
As of 11:11 AM Eastern
This is a fair market value price provided by Massive. Learn more.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Jin Medical International stock logo

Jin Medical International NASDAQ:ZJYL

$3.38 +0.02 (+0.45%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.